search
Back to results

Health Dialogue Intervention Versus Opportunistic Screening for Type 2 Diabetes and Cardiovascular Disease Prevention

Primary Purpose

Cardiovascular Diseases, Type 2 Diabetes

Status
Not yet recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Health Dialogue Intervention
Opportunistic Screening
Sponsored by
Region Stockholm
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiovascular Diseases

Eligibility Criteria

50 Years - 59 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Primary care centres with a Care Need Index above 1.0 Patients listed at the participating primary care centers. Exclusion Criteria: • None.

Sites / Locations

  • Center for epidemiology and community medicine, Region Stockholm

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Health Dialogue Intervention

Opportunistic Screening

Arm Description

Outcomes

Primary Outcome Measures

Change in systolic blood pressure (mmHg)
Measured by care providers in accordance with routine guidelines

Secondary Outcome Measures

Full Information

First Posted
September 27, 2023
Last Updated
October 10, 2023
Sponsor
Region Stockholm
Collaborators
Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT06067178
Brief Title
Health Dialogue Intervention Versus Opportunistic Screening for Type 2 Diabetes and Cardiovascular Disease Prevention
Official Title
Effectiveness of a Health Dialogue Intervention Versus Opportunistic Screening in Primary Care for Type 2 Diabetes and Cardiovascular Disease Prevention in Low Socioeconomic Settings - The DETECT Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
April 2025 (Anticipated)
Study Completion Date
April 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Stockholm
Collaborators
Karolinska Institutet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic diseases such as cardiovascular disease and diabetes type 2 are major causes of death worldwide. Preventive interventions can be delivered through primary care, as this is the first-line healthcare with which a considerable proportion of the population comes into contact every year. The goal of this cluster-randomized trial is to compare the effects of a Health Dialogue Intervention (HDI) to Opportunistic Screening (OS) in primary care among middle-aged adults with low socioeconomic status. The main questions it aims to answer are: What is the short-term change in cardiovascular risk factors, lifestyle behaviors, and perceived quality-of-life among participants offered HDI, as compared to participants offered OS? What is the long-term risk of ischemic heart disease, stroke, type 2 diabetes, and death due to cardiovascular disease or type 2 diabetes, among participants offered HDI, as compared to participants offered OS?
Detailed Description
DETECT (health Dialogue intErvention versus opporTunistic scrEening in primary Care for Type 2 diabetes and cardiovascular disease prevention) targets the challenges of primary prevention for individuals with low socioeconomic status by implementing and evaluating two preventive interventions, a Health Dialogue Intervention (HDI) and an Opportunistic Screening (OS), conducted in primary care, specifically targeting settings with low socioeconomic status. The interventions will focus on detecting risk factors for CVD and supporting changes in unhealthy lifestyle behaviors. The study is designed as a parallel cluster-randomized trial with two conditions, with primary care centers (PCCs) serving as the unit of randomization and individual patients as units of observation for primary and secondary outcomes. Participants randomized to the HDI intervention will be invited to partake in a systematic screening of cardiovascular and metabolic risk factors using questionnaires, blood sampling, and clinical examinations, all of which together form the risk profile. Next, they will be invited to an individually oriented health dialogue which is prescribed by a care provider. The dialogue focuses on promoting healthy lifestyle behaviors and is based on the screening results and the given risk profile. The effects of HDI will be compared to that from OS, wherein participants upon a scheduled appointment in primary care for whichever reason are also screened for hypertension, overweight/obesity, smoking status, blood-lipid profile, and blood glucose. Short-term outcomes will be assessed at baseline, and 6 and 12-months after receiving the intervention, and long-term outcomes (i.e. 5 and 10 years post intervention) using nationwide registers. The goal is to recruit a total of 30 PCCs (n=15 in each arm) in the county of Stockholm. Based on real observed variance in levels of systolic blood pressure in the county of Stockholm and accounting for clustering effects, the investigators calculate that a minimum of 840 participants (n=420 in each arm and n=28 per cluster) would yield 80% power to detect a reduction of 5 mmHg systolic blood pressure in the HDI group. To allow for the expected difficulties with recruitment and subsequent attrition, the investigators therefore aim to recruit n=100 patients per cluster, yielding a total study population of 3000. The data will be primarily analyzed according to an intention-to-treat approach; that is, individuals will be considered exposed to the intervention to which their PCC has been randomized. The two experimental groups will be compared to estimate the effectiveness. Intention-to-treat analyses will be complemented by per-protocol analyses, where the effects of the interventions will be estimated only among participants who will receive the intervention according to the protocol foreseen. Linear regression will be used to estimate differences at follow-up in the means of continuous outcomes, whereas logistic regression was used in the analysis of dichotomous outcomes. In the intention-to-treat analyses the investigators will also estimate the number needed to treat to achieve one unit of the projected change in the corresponding outcome as 1/ARR (absolute risk reduction). The hierarchical structure of the data due to the cluster design will be considered through the use of mixed regression models, with random effects at the PCC level and fixed effects at the intervention level.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Type 2 Diabetes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Pragmatic, cluster-randomized trial
Masking
Investigator
Allocation
Randomized
Enrollment
3000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Health Dialogue Intervention
Arm Type
Experimental
Arm Title
Opportunistic Screening
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Health Dialogue Intervention
Intervention Description
Lifestyle assessment: All participants fill out a questionnaire to assess behavioral risk factors for CVD and undergo blood tests for cholesterol and blood glucose. Lifestyle health dialogue: When presenting in person at the primary care center, blood pressure, BMI, and waist-hip ratio will be measured. The results from the questionnaire, blood tests, blood pressure, and body measurements will be summarized using a visual tool, in which risk factors are graded into risk levels to estimate CVD risk. The visual tool will then be used in the health dialogue to discuss risk factors. The health dialogue is conducted by a licensed healthcare professional who has been trained in the methodology. The dialogue will be conducted in a person-centered manner and will aim to motivate and support lifestyle behavior changes when needed. If necessary, medical treatment will be provided according to existing guidelines.
Intervention Type
Other
Intervention Name(s)
Opportunistic Screening
Intervention Description
Risk factor assessment: Opportunistic screening entails screening for risk factors (blood pressure, BMI, blood tests for cholesterol and blood glucose, and smoking) among patients visiting the primary care center for another reason. Screening is conducted by a healthcare professional at which the patient has an appointment. Detected risk factors for CVD are treated according to the existing care programs and guidelines at the primary care center, which should always include lifestyle advice as the first intervention and medication if hypertension is established. In this intervention, there is a more limited assessment of behavioral risk factors; that is, patients are asked about smoking, but assessment of diet, physical activity, or alcohol consumption is not included in the opportunistic screening.
Primary Outcome Measure Information:
Title
Change in systolic blood pressure (mmHg)
Description
Measured by care providers in accordance with routine guidelines
Time Frame
Baseline (defined as time of HDI/OS), 6 months post intervention, 12 months post intervention
Other Pre-specified Outcome Measures:
Title
Change in blood cholesterol levels
Description
Measured by care providers in accordance with routine guidelines
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in blood glucose levels
Description
Measured by care providers in accordance with routine guidelines
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in body-mass-index
Description
Measured by care providers in accordance with routine guidelines
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in quality-of-life
Description
Measured by EQ-5D (EuroQol-5 Dimension). From the five dimensions, a summary index is derived, with a maximum score of 1, where 1 indicates the best health state. Additionally, a visual analogue scale (VAS) indicates the general health status from 0 to 100, with 100 indicating the best health status.
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in smoking status
Description
Measured by self-reported questionnaires
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in dietary habits
Description
Measured by self-reported questionnaires
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in alcohol consumption
Description
Measured by self-reported questionnaires
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Change in physical activity
Description
Measured by self-reported questionnaires
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Incidence of ischemic heart disease
Description
Collected from national registries
Time Frame
5 and 10 years post intervention
Title
Incidence of stroke
Description
Collected from national registries
Time Frame
5 and 10 years post intervention
Title
Incidence of type 2 diabetes
Description
Collected from national registries
Time Frame
5 and 10 years post intervention
Title
Mortality due to cardiovascular disease or type 2 diabetes
Description
Collected from national registries
Time Frame
5 and 10 years post intervention
Title
Healthcare costs in the health dialogue group vs. the opportunistic screening group
Description
Administrative data collected form health care providers
Time Frame
12 months post intervention
Title
Costs per attained blood pressure target among individuals in the health dialogue group vs. the opportunistic screening group
Description
Administrative data collected form health care providers
Time Frame
12 month post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
59 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Primary care centres with a Care Need Index above 1.0 Patients listed at the participating primary care centers. Exclusion Criteria: • None.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanna Augustsson, PhD
Phone
+468-123 371 26
Email
hanna.augustsson@regionstockholm.se
First Name & Middle Initial & Last Name or Official Title & Degree
Marcel Ballin, PhD
Phone
+468-123 371 63
Email
marcel.ballin@regionstockholm.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hanna Augustsson, PhD
Organizational Affiliation
Center for epidemiology and community medicine, Region Stockholm
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for epidemiology and community medicine, Region Stockholm
City
Stockholm
ZIP/Postal Code
10435
Country
Sweden
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henna Hasson, PhD
Email
henna.hasson@regionstockholm.se
First Name & Middle Initial & Last Name & Degree
Hanna Augustsson, PhD
First Name & Middle Initial & Last Name & Degree
Marcel Ballin, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Individual participant data will not be shared in accordance with Swedish law and regulations.

Learn more about this trial

Health Dialogue Intervention Versus Opportunistic Screening for Type 2 Diabetes and Cardiovascular Disease Prevention

We'll reach out to this number within 24 hrs